What Happens When You Stop Taking Citalopram: What the Research Generally Shows

Citalopram is a selective serotonin reuptake inhibitor (SSRI) — one of the most widely prescribed classes of antidepressants in the world. Questions about stopping it are common, and the experiences people report when discontinuing SSRIs are well-documented in the medical literature. Understanding what research generally shows about the discontinuation process can help people have more informed conversations with their prescribing physician.

This article does not advise anyone to stop, continue, or change their medication. That decision belongs entirely to a qualified healthcare provider who knows the individual's full clinical picture.

What Stopping an SSRI Actually Involves

Citalopram works by blocking the reuptake of serotonin in the brain, which increases serotonin availability in synaptic spaces. When someone takes it consistently, the brain adjusts to this altered serotonin environment over time. When the medication is reduced or stopped, the nervous system has to re-adapt — and that process is not always smooth or immediate.

Research distinguishes between two separate phenomena that are often confused:

• Discontinuation syndrome — a set of physical and psychological symptoms that can arise when stopping or rapidly reducing an SSRI
• Return of the original condition — symptoms of depression or anxiety that may re-emerge after medication is stopped

These are distinct experiences, though they can overlap in timing, which makes them genuinely difficult to tell apart without clinical guidance.

What Research Generally Shows About Discontinuation Syndrome

Discontinuation symptoms are well-recognized in the scientific and clinical literature. They are not a sign of addiction in the traditional sense — SSRIs are not considered addictive substances — but the nervous system's adaptation to the drug means abrupt stopping can produce real, sometimes disruptive effects.

Commonly reported discontinuation symptoms in the literature include:

• "Brain zaps" — brief electrical shock-like sensations in the head
• Dizziness and balance disturbances
• Nausea and gastrointestinal upset
• Flu-like symptoms (fatigue, muscle aches)
• Irritability, anxiety, or emotional volatility
• Sleep disruption and vivid dreams

These symptoms typically appear within 2–4 days of stopping or significantly reducing the dose, and in most cases resolve within 1–2 weeks, according to published clinical reviews. However, a subset of people report symptoms that persist for weeks or months — a phenomenon receiving increasing attention in psychiatric research, sometimes referred to as Post-Discontinuation Persistent Syndrome (PDPS), though this remains an area of active study and ongoing debate about prevalence and mechanism.

What Some People Report Noticing After Stopping 🌿

Beyond discontinuation syndrome, some people report subjective changes after they and their doctor have determined the medication is no longer needed. These are not "benefits" of stopping the medication in a clinical sense — rather, they reflect changes that some individuals notice when serotonin reuptake is no longer being pharmacologically altered.

Commonly reported subjective experiences in surveys and qualitative research include:

It's important to be direct: these are self-reported experiences that vary enormously across individuals. They do not occur universally, and for many people, the benefits of staying on the medication significantly outweigh any such changes.

The Variables That Shape Individual Outcomes

What someone experiences after stopping citalopram depends heavily on individual factors — and the range of outcomes is wide.

Factors that influence discontinuation experience:

• Duration of use — People who have taken SSRIs for years tend to have more pronounced discontinuation effects than short-term users
• Dose at the time of stopping — Higher doses are generally associated with more pronounced symptoms
• Tapering vs. abrupt stopping — Gradual dose reduction (tapering) is associated with milder and shorter discontinuation symptoms in most clinical guidance
• Individual neurochemistry — People differ significantly in how their serotonin systems respond to changes in drug levels
• Metabolism and genetics — Variations in the CYP2C19 enzyme affect how quickly citalopram is processed, which influences how the body responds to removal of the drug
• Underlying mental health status — Someone whose depression or anxiety is in remission faces a very different situation than someone who discontinued prematurely

The Spectrum of Outcomes

On one end: a person who has completed a full course of treatment, tapered slowly under supervision, and whose underlying condition is fully resolved may experience little to no disruption and feel genuinely well after stopping. 🧠

On the other end: someone who stops abruptly after years of use during a period of ongoing stress may experience significant discontinuation symptoms, followed by a return of the original condition — sometimes more intensely than before, an effect noted in the research literature.

Most people fall somewhere between these points. Discontinuation syndrome is manageable for many, but for others it is prolonged and distressing. Research on predicting who will have which experience remains limited.

The Missing Piece

What the research cannot account for is the individual standing behind the search query — their diagnosis, how long they've been on citalopram, their current dose, their overall mental health trajectory, their history with the medication, and what led them to ask this question in the first place. Those details are what make the difference between a transition that goes smoothly and one that doesn't.